Amgen (AMGN) Cash & Equivalents (2009 - 2026)

Amgen's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $12.0 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 36.64% year-over-year to $12.0 billion; the TTM figure through Mar 2026 stood at $12.0 billion (up 36.64% YoY), while the FY2025 annual figure was $9.1 billion, down 23.75% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $12.0 billion, up from $9.1 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $34.7 billion in Q3 2023, with the low at $5.2 billion in Q2 2022.
• The 5-year median for Cash & Equivalents is $9.4 billion (2025), against an average of $13.4 billion.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents soared 557.31% in 2023, then tumbled 74.03% in 2024.
• Amgen's Cash & Equivalents stood at $7.6 billion in 2022, then surged by 43.45% to $10.9 billion in 2023, then advanced by 9.4% to $12.0 billion in 2024, then slipped by 23.75% to $9.1 billion in 2025, then surged by 31.87% to $12.0 billion in 2026.
• Business Quant data shows AMGN's Cash & Equivalents at $12.0 billion in Q1 2026, $9.1 billion in Q4 2025, and $9.4 billion in Q3 2025.